combine@alvar.ug

RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials

RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials

Show simple record

dc.contributor.author Machteld van den Berg
dc.contributor.author Bernhards Ogutu
dc.contributor.author Nelson Sewankambo
dc.contributor.author Nikola Biller-Andorno
dc.contributor.author Marcel Tanner
dc.date.accessioned 2021-01-11T13:51:56Z
dc.date.available 2021-01-11T13:51:56Z
dc.date.issued 2019
dc.identifier.uri https://combine.alvar.ug/handle/1/49730
dc.description.abstract Abstract; A malaria vaccine as part of the integrated malaria control and elimination efforts will have a major impact on public health in sub-Sahara Africa. The first malaria vaccine, RTS,S, now enters pilot implementation in three African countries. These pilot implementation studies are being initiated in Kenya, Malawi and Ghana to inform the broader roll-out recommendation. Based on the malaria vaccine clinical trial experiences, key ethical practices for effective clinical trial research in low-resource settings are described. For successful vaccine integration into malaria intervention programs, the relational dynamics between researchers and trial communities must be made explicit. Incorporating community values and returning to research practices that serve the intended benefactors are key strategies that address the human realities in large-scale clinical trials and pilot implementation, leading to positive public health outcomes.
dc.publisher Research Square
dc.title RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials
dc.type Preprint
dc.identifier.doi 10.21203/rs.2.142/v2
dc.identifier.lens 115-518-488-158-537


This record appears in the collections of the following institution(s)

Show simple record

Search Entire Database


Browse

My Account